Representation and inclusion in clinical trials
Paving the way for inclusive clinical trials: establishing a platform for improvement
Advancements in AI for site selection
Learn how ICON is using human-enabled AI to efficiently integrate, interrogate and interpret large datasets from multiple sources and gain valuable insights for site selection in both expected and unexpected ways.
Equity and inclusion in rare disease clinical trials: beyond buzzwords
The rarity of each individual rare disease introduces many unique challenges and complexity in clinical research including barriers to achieving representative trial populations and equitable access to trials.
.png?crop=yes&w=982&h=600&a=938,0&itok=r0pMiSn- "11828-005-Front-Page-Banner_Subpage-banner_1-(1)"){kind=icon}
Inclusion in clinical trials whitepaper
Examining how the field of clinical research currently approaches inclusive enrolment gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.
The promise of decentralised models and inclusion in clinical trials
ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations currently (or are likely to) address representation and inclusion in clinical trials into the future.
Representative clinical trials in a post-pandemic world
Inclusive clinical research has been a major topic of discussion for years, but it took the COVID-19 pandemic for the biopharma industry to fully realise the importance of recruiting representative populations into studies.
